JCI The Journal of Clinical Investigation

A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma

Benjamin Ory, … , S. Michael Rothenberg, Leif W. Ellisen

J Clin Invest. 2014;124(3):1418-1418. https://doi.org/10.1172/JCI75406.

Corrigendum

Original citation: J. Clin. Invest. 2011;121(2):809–820. doi:10.1172/JCI43897. Citation for this corrigendum: J. Clin. Invest. 2014;124(3):1418. doi:10.1172/JCI75406. During the assembly of Figure 1A of this manuscript, incorrect β-tubulin immunoblots were inadvertently included. The authors were unable to retrieve the original raw data; however, results from a replicate experiment are shown in the corrected figure panel below. The authors regret the error.

Corrigendum

A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma

Benjamin Ory, Matthew R. Ramsey, Catherine Wilson, Douangsone D. Vadysirisack, Nicole Forster, James W. Rocco, S. Michael Rothenberg, and Leif W. Ellisen

Original citation: *J Clin Invest*. 2011;121(2):809–820. doi:10.1172/JCI43897.

Citation for this corrigendum: *J Clin Invest*. 2014;124(3):1418. doi:10.1172/JCI75406.

During the assembly of Figure 1A of this manuscript, incorrect β-tubulin immunoblots were inadvertently included. The authors were unable to retrieve the original raw data; however, results from a replicate experiment are shown in the corrected figure panel below.

The authors regret the error.



Corrigendum

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

Violeta Serra,[1] Pieter J.A. Eichhorn,[2] Celina García-García,[1] Yasir H. Ibrahim,[1] Ludmila Prudkin,[3] Gertrudis Sánchez,[3] Olga Rodríguez,[1] Pilar Antón,[1] Josep-Lluís Parra,[4] Sara Marlow,[5] Maurizio Scaltriti,[6] José Pérez-Garcia,[7] Aleix Prat,[8] Joaquín Arribas,[4,9] William C. Hahn,[10,11] So Young Kim,[12] and José Baselga[1,6]

[1]Experimental Therapeutics, Vall d'Hebron Institute of Oncology, Barcelona, Spain. [2]Cancer Science Institute of Singapore, National University of Singapore, Singapore. [3]Molecular Pathology and [4]Growth Factors Groups, Vall d'Hebron Institute of Oncology, Barcelona, Spain. [5]Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA. [6]Human Oncology and Pathogenesis Program and Memorial Sloan-Kettering Cancer Center, New York, New York, USA. [7]Breast Cancer and Melanoma Group and [8]Translational Genomics Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain. [9]Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. [10]Center for Cancer Genome Discovery, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA. [11]Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. [12]Department of Molecular Genetics and Microbiology, Duke RNAi Screening Facility, Duke University Medical Center, Durham, North Carolina, USA.

Original citation: *J Clin Invest*. 2013;123(6):2551–2563. doi:10.1172/JCI66343.

Citation for this corrigendum: *J Clin Invest*. 2014;124(3):1418. doi:10.1172/JCI75534.

The affiliation for Joaquín Arribas was incorrect. The correct affiliation list is above.

The authors regret the error.